Emergent Biosolutions Inc (EBS) : New Amsterdam Partnersny reduced its stake in Emergent Biosolutions Inc by 1.21% during the most recent quarter end. The investment management company now holds a total of 108,262 shares of Emergent Biosolutions Inc which is valued at $3,293,330 after selling 1,331 shares in Emergent Biosolutions Inc , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Emergent Biosolutions Inc makes up approximately 0.77% of New Amsterdam Partnersny’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in EBS in the latest quarter, The investment management firm added 3,663 additional shares and now holds a total of 68,111 shares of Emergent Biosolutions Inc which is valued at $2,071,937. Calamos Advisors sold out all of its stake in EBS during the most recent quarter. The investment firm sold 10,100 shares of EBS which is valued $341,178.Louisiana State Employees Retirement System boosted its stake in EBS in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 13,800 shares of Emergent Biosolutions Inc which is valued at $466,164. Emergent Biosolutions Inc makes up approx 0.02% of Louisiana State Employees Retirement System’s portfolio. Old Mutual Global Investors (uk) Ltd. sold out all of its stake in EBS during the most recent quarter. The investment firm sold 29,257 shares of EBS which is valued $946,171.
Emergent Biosolutions Inc opened for trading at $30.62 and hit $30.98 on the upside on Thursday, eventually ending the session at $30.69, with a gain of 0.89% or 0.27 points. The heightened volatility saw the trading volume jump to 6,14,589 shares. Company has a market cap of $1,229 M.
On the company’s financial health, Emergent Biosolutions Inc reported $-0.27 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.17. The company had revenue of $101.49 million for the quarter, compared to analysts expectations of $111.12 million. The company’s revenue was down -19.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.36 EPS.
Many Wall Street Analysts have commented on Emergent Biosolutions Inc. Shares were Reiterated by Singular Research on Jun 28, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $44 .
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.